600 children from 15 clinical sites in the United States will be randomized into one of two groups, antimicrobial prophylaxis or placebo. Participants will be closely monitored by telephone contact , clinic visits and DMSA renal scan
600 children from 15 clinical sites in the United States will be randomized into one of two groups, antimicrobial prophylaxis or placebo. Participants will be closely monitored by telephone contact , clinic visits and DMSA renal scan
The primary purpose of the study is to determine whether daily antimicrobial prophylaxis is superior to placebo in managing children with Vesicoureteral Reflux (VUR)
Childen age 1 month to 6 years, with documented first or second UTI prior to VUR diagnosis, VUR grade I-IV based on VCUG
up to $150.00 at completion of 24 month enrollment
Saul P. Greenfield, MD
Name: Allyson Fried, MS, PNP
Phone: 716-878-7306
Email: afried@kaleidahealth.org